Clinical Trials Directory

Trials / Conditions / Severe Asthma

Severe Asthma

87 registered clinical trials studyying Severe Asthma30 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingTezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
NCT06998095
AstraZeneca
Not Yet RecruitingA Phase 2 Dose Ranging Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients
NCT07532265
Kinaset Therapeutics IncPhase 2
Not Yet RecruitingTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)
NCT06705764
University of AlbertaPhase 4
RecruitingPhase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
NCT07363642
AstraZenecaPhase 3
RecruitingA Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (S
NCT07359846
Generate BiomedicinesPhase 3
RecruitingRemission in Adults With Severe Asthma in Thailand
NCT07328035
Thammasat University
RecruitingA Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (S
NCT07276724
Generate BiomedicinesPhase 3
RecruitingDownstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
NCT07139899
Bastiaan Driehuys
Enrolling By InvitationBeyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in
NCT07343661
Azienda Ospedaliero Universitaria di CagliariPhase 4
RecruitingReal-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis
NCT07530770
Qianfoshan Hospital
Not Yet RecruitingPotency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients W
NCT07013123
University Hospital, MontpellierPhase 3
RecruitingEvaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Severe Asthma
NCT06985225
University of Kansas Medical Center
Active Not RecruitingA Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479
Upstream Bio Inc.Phase 2
Not Yet RecruitingWithdrawal of Dupilumab in Severe Asthma
NCT06818019
University Hospital, ToulousePhase 4
CompletedCharacterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)
NCT07218172
AstraZeneca
RecruitingExperience of Biologic Treatments for Severe Asthma: a Survey
NCT06903780
Royal Devon and Exeter NHS Foundation Trust
Not Yet RecruitingThe Inflammatory Profile of Exacerbations in Patients With Severe Asthma Receiving Tezepelumab: The TezEx Stud
NCT06666504
Guy's and St Thomas' NHS Foundation Trust
RecruitingExploring the Lived Experience of Young Adults With Severe Asthma
NCT06681545
Manchester University NHS Foundation Trust
CompletedDigital Self-Monitoring in Severe Asthma
NCT07393984
University of Medicine and Pharmacy "Victor Babes" TimisoaraN/A
Active Not RecruitingOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clini
NCT06473779
AstraZenecaPhase 3
Active Not RecruitingReal-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in R
NCT06566885
AstraZeneca
CompletedObservational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelum
NCT06487065
AstraZeneca
RecruitingClinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)
NCT06472310
AstraZeneca
CompletedPatient Characteristics, Treatment Patterns and Outcomes of Patients With Severe Asthma Treated With Tezepelum
NCT06455462
AstraZeneca
RecruitingBronchial Thermoplasty for Adults With Severe Asthma in the Biologic Era
NCT07292805
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)N/A
CompletedPROPE Severe Asthma Study in Egypt
NCT06283290
AstraZeneca
Enrolling By InvitationImpact of Respiratory Allergy on Response to Initiation of Biotherapy in Severe Asthma in Adult Severe Asthmat
NCT06916104
Poitiers University Hospital
CompletedA Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma
NCT06196879
Upstream Bio Inc.Phase 2
Enrolling By InvitationK-HEALTH in AIR - Barcelona Pilot - Cohort
NCT06421402
Institut d'Investigacions Biomèdiques August Pi i Sunyer
UnknownThe BASA Study: Breath Analysis for Severe Asthma Patients
NCT05946421
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Active Not RecruitingUsing NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Larg
NCT06389058
San Diego State University
Not Yet RecruitingSevere Eosinophilic Asthma Phenotypes During Childhood Have Various Origins
NCT05762627
Assistance Publique - Hôpitaux de Paris
CompletedPatient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients
NCT05603845
AstraZeneca
CompletedModeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)
NCT05616338
University Hospital, MontpellierN/A
CompletedEvaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.
NCT05472324
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2
CompletedEvaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
NCT05576454
Bio-Thera SolutionsPhase 1
Recruiting3TR Asthma Biologics Cohort (ABC) Study
NCT06126692
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
RecruitingPredictive Signature of Benralizumab Response
NCT04565483
Nantes University HospitalPhase 4
RecruitingEvaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma
NCT05018299
Oneness Biotech Co., Ltd.Phase 2
UnknownSevere Asthma Exacerbations and Mepolizumab Treatment
NCT04914078
Università degli Studi di Ferrara
CompletedStudy in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and Outcomes
NCT07159295
AstraZeneca
CompletedAdapting Body Reprogramming for Severe Asthma: a Feasibility Study
NCT04980755
Royal Devon and Exeter NHS Foundation TrustN/A
UnknownFollow-up of Children With Severe Asthma at Adult Age
NCT05032209
Assistance Publique - Hôpitaux de Paris
UnknownDefining the Severe Paediatric Asthma Endotype
NCT04680117
Assistance Publique - Hôpitaux de ParisN/A
RecruitingPhenotyping Asthma for Bronchial Thermoplasty
NCT03435237
Massachusetts General Hospital
UnknownPortuguese Severe Asthma Registry: Getting Answers for Severe Asthma Patients
NCT04714567
Sociedade Portuguesa de Pneumologia
CompletedImpulse Oscillometry Measurements in Severe Eosinophilic Asthmatics Before and After Anti-IL-5 Factor Initiati
NCT05147155
University of Thessaly
CompletedReal Life Experience Survey of Dupilumab in the Netherlands
NCT05331755
Gert-Jan Braunstahl
UnknownFlow Cytometry Analysis of Eosinophils in Severe Asthma Patients.
NCT05001529
Scarlata, Simone, M.D.Phase 4
CompletedEffectiveness of Anti-IL-5/IL5R Inhibitors
NCT06239441
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
CompletedObservational Retrospective Study on Clinical Outcomes of Patients Receiving Benralizumab in Spain.
NCT04648839
AstraZeneca
UnknownEfficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)
NCT04612556
Aristotle University Of Thessaloniki
CompletedClinical Characteristics of Severe Childhood Asthma
NCT06024902
Children's Hospital of Fudan University
UnknownPhenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
NCT04463836
Imperial College London
UnknownNational Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotyp
NCT04438408
University Hospital, Toulouse
RecruitingDeployment o the Multidisciplinary Prospective Cohort Imminent
NCT04334031
University Hospital, LilleN/A
UnknownPrecision Medicine Intervention in Severe Asthma (PRISM) Study
NCT05164939
Asan Medical Center
CompletedChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab
NCT04272463
AstraZeneca
WithdrawnBenralizumab in the Treatment of Patients With Severe Asthma With ABPA
NCT04108962
Baylor Research InstitutePhase 4
CompletedPatient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Bel
NCT04221802
AstraZeneca
CompletedLong-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma
NCT04048343
AstraZenecaPhase 3
CompletedPrevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
NCT03931954
AstraZeneca
RecruitingSwiss Severe Asthma Register
NCT03984253
Prof. Dr. Jörg Leuppi
UnknownStudy of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
NCT03476109
Cliniques universitaires Saint-Luc- Université Catholique de LouvainPhase 4
CompletedNational Validation and Sensitivity to Change of the SAQ
NCT04031261
University Hospital Plymouth NHS Trust
CompletedBRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS)
NCT03925415
AstraZeneca
RecruitingInternational Severe Asthma Registry: Canadian Cohort
NCT04045587
University of British Columbia
CompletedDupilumab for Severe Asthma in a Real Life Setting
NCT04022447
Assistance Publique - Hôpitaux de Paris
UnknownClinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up
NCT03532685
University of Sao Paulo General HospitalN/A
CompletedCharacterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to b
NCT03629782
AstraZeneca
UnknownRussian Severe Asthma Registry
NCT03608566
Interregional Public Organization, Russian Respiratory Society
CompletedAssessment of Treatment Patterns of Severe Asthmatic Patients Across the Gulf Region - SevEos Study
NCT03387722
AstraZeneca
UnknownPredictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.
NCT03377920
Universitair Ziekenhuis BrusselN/A
CompletedReslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab
NCT03074942
Sociedad Española de Neumología y Cirugía TorácicaPhase 2
RecruitingSevere Asthma Network Italy
NCT06625216
Società Italiana di Allergologia, Asma e Immunologia Clinica
WithdrawnType 2 Innate Lymphoid Cells in Severe Pediatric Asthma
NCT03784781
Assistance Publique - Hôpitaux de Paris
CompletedAfrican Severe Asthma Program: A Research Network for Characterisation of Severe Asthma in Africans (ASAP)
NCT03065920
Makerere University
UnknownUnraveling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma (TASMA) Extension Study
NCT02975284
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Unknown"SEVERE ASTHMA" in the COMMUNITY
NCT01961258
Meir Medical Center
Active Not RecruitingEffect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
NCT04520165
University of Liege
WithdrawnTrial of Simvastatin for the Treatment of Severe Asthma
NCT02433535
University of California, DavisPhase 2
Active Not RecruitingCohort Analysis of Clinical and Biological Severe Childhood Asthma
NCT02114034
Assistance Publique - Hôpitaux de Paris
UnknownClinico-biological Correlation of Severe Asthma in Children
NCT02038374
Assistance Publique Hopitaux De MarseilleN/A
CompletedBIOmarkers in Severe AsthMa Patients on Omalizumab Treatment
NCT03361111
Medical University of Warsaw
RecruitingRegister Schweres Asthma - German Asthma Net e.V.
NCT06035289
German Asthma Net e.V.
CompletedBronchial Thermoplasty in Severe Persistent Asthma
NCT01350336
Boston Scientific CorporationN/A
CompletedTreatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder
NCT00621946
University of Texas Southwestern Medical CenterPhase 4